{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', '12.7.2.', 'References', 'Andrade RJ, Robles M, Lucena MI. Rechallenge in drug-induced liver injury: the', 'attractive hazard. Expert Opin Drug Saf. 2009;8:709-714.', 'Hunt, CM. Mitochondrial and immunoallergic injury increase risk of positive drug', 'rechallenge after drug-induced liver injury: A systematic review. Hepatol. 2010;52:2216-', '2222.', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen', 'Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', 'Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, D\u00e9ny P, Gault E. Quantification', 'of Hepatitis Delta Virus RNA in Serum by Consensus Real-Time PCR Indicates', 'Different Patterns of Virological Response to Interferon Therapy in Chronically Infected', 'Patients. J Clin Microbiol. 2005;43(5):2363-2369.', 'Papay JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, Hunt CM. Drug-induced liver', 'injury following positive drug rechallenge. Regul Tox Pharm. 2009;54:84-90.', '131']['2017N330177_04', 'CONFIDENTIAL', '205678', '12.8.', 'Appendix 8: ECOG Performance Status', 'Grade', 'Descriptions', '0', 'Normal activity. Fully active, able to carry on all pre-disease performance without restriction.', '1', 'Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able', 'to carry out work of a light or sedentary nature (e.g., light housework, office work).', '2', 'In bed <50% of the time. Ambulatory and capable of all self-care, but unable to carry out any', 'work activities. Up and about more than 50% of waking hours.', '3', 'In bed >50% of the time. Capable of only limited self-care, confined to bed or chair more than', '50% of waking hours.', '4', '100% bedridden. Completely disabled. Cannot carry on any self-care. Totally confined to bed', 'or chair.', '5', 'Dead.', 'Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of', 'the Eastern Cooperative Oncology Group. American journal of clinical oncology. 1982 Dec 1;5(6):649-56.', '132']['2017N330177_04', 'CONFIDENTIAL', '205678', '12.9.', 'Appendix 9: GSK Corneal Event Severity Scale and', 'Mitigation Strategy for GSK2857916 Treatment-Related', 'Corneal Events', 'In order to minimize corneal events associated with GSK2857916, participants must', 'receive steroid eye drops as prophylaxis (such as: prednisolone acetate 1%, prednisolone', 'phosphate 1%, dexamethasone 0.1% or equivalent) 1 drop QID starting 1 day prior to', 'each GSK2857916 infusion, and continuing for a total of consecutive 7 days. Omission', 'or discontinuation of prophylactic steroid eye drops may be allowed under certain', 'circumstances (e.g., in the setting of intolerability, contraindication, or toxicity secondary', 'to steroid eye drops) upon discussion with the Medical Monitor.', 'Prophylactic preservative-free artificial tears should be administered in each eye at least 4', 'to 8 times daily beginning on Cycle 1 Day 1 until the EOT. Allow at least 5-10 minutes', 'between administration of artificial tears and steroid eye drops. In the event of ocular', 'symptoms (e.g., dry eyes), the use of artificial tears may be increased up to every 2 hours', 'as needed.', 'While not yet clinically demonstrated, it is theoretically possible that the application of a', 'cooling eye mask during GSK2857916 administration, and in the first few hours after', 'infusion may subsequently decrease ocular side effects. On the day of infusion at the', 'discretion of the participant and the investigator, the following may be considered:', 'Beginning with the start of each GSK2857916 infusion, participants may apply', 'cooling eye masks to their eyes for approximately 1 hour or as much as tolerated.', 'Participants may continue using the cooling eye mask beyond the first hour for up to', \"4 hours. Further use beyond 4 hours is at the participant's discretion.\", 'Participants must avoid the use of contact lenses during the study.', 'An ophthalmology (or optometry, if ophthalmology is not available) consult is required', 'for all participants who develop signs or symptoms of corneal events or require steroid', 'eye drops for more than 7 days.', 'Following discussions with regulatory agencies, GSK developed a grading scale for', 'corneal events to capture both corneal findings and visual acuity changes in participants', 'treated with GSK2857916. This GSK scale is different from CTCAE criteria for eye', \"disorders which relies mainly on patient's symptoms and patient's ability to attend to\", \"'activities of daily living' for grading of events.\", 'A summary of prophylactic interventions for corneal events associated with', 'GSK2857916 is provided in Table 21. In addition to reporting eye disorders using', 'CTCAE 4.03 criteria, corneal events associated with GSK2857916 must be graded', 'according to the guidelines provided in Table 22. Additional guidance on visual acuity', 'changes is provided in Table 23.', 'In the FTIH study (BMA117159), eye examinations showed that most participants', 'continued to receive GSK2857916 dose when either a GSK Scale Grade 2 corneal', 'examination finding or a 2-3-line decrease in visual acuity was reported. With this dosing', '133']\n\n###\n\n", "completion": "END"}